Pharsight

Fycompa generic

Fycompa is an anti-epileptic drug owned by Eisai Inc. It contains the active ingredient perampanel and was first authorized for market use on 29 April, 2016. The drug is available in suspension;oral dosage forms and has a total of 2 patents.

When will Fycompa generic be available?

The generic of Fycompa is expected to be available after 01 July, 2026. This follows the expiry of the last patent held by Eisai Inc., which is due on the same date.

Fycompa uses

Fycompa is used for the treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy 12 years of age and older. It also treats partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older. The active ingredient perampanel contributes to its efficacy in managing these conditions.

Fycompa patent expiration

Fycompa, owned by Eisai Inc., is protected by 2 patents. The last patent protecting Fycompa from generic entry, titled 'Method for producing 1, 2-dihydropyridine-2-one compound', expires on 2026-07-01. Fycompa generic will not be available until this date. Below are the details of the patent:

Fycompa dosage

Want to ask something?